References
- Harada M, Osuga Y. Fertility preservation for female cancer patients. Int J Clin Oncol. 2019;24(1):28–33.
- Romao RL, Lorenzo AJ. Fertility preservation options for children and adolescents with cancer. Can Urol Assoc J. 2017;11(1–2):S97–S102.
- Sanada Y, Harada M, Kunitomi C, Kanatani M, Izumi G, Hirata T, et al. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. J Obstet Gynaecol Res. 2019;45(10):2021–8.
- Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for anca-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
- Blumenfeld Z, Mischari O, Schultz N, Boulman N, Balbir-Gurman A. Balbir-Gurman A: Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in sle and autoimmune diseases. Semin Arthritis Rheum. 2011;41(3):346–52.
- Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the eular recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45.
- Henes M, Henes JC, Neunhoeffer E, Von Wolff M, Schmalzing M, Kotter I, et al. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the fertiprotekt network. Lupus 2012;21(9):953–8.
- Elizur SE, Chian RC, Pineau CA, Son WY, Holzer HEG, Huang JYF, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford). 2008;47(10):1506–9.
- Huong DL, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Lefebvre G, et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum.2002;32(3):174–88.
- Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin MD. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum.2000;43(3):550–6.
- Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831–7.
- Boumpas DT, Austin HA, 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119(5):366–9.